

Burden and pattern of micro vascular complications in type 2 diabetes in a tertiary health institution in Nigeria.

Michael Olamoyegun¹, Waheed Ibraheem², Sandra Iwuala³, Morenike Audu⁴, Babatope Kolawole⁵

1. LAUTECH Teaching Hospital, and College of Health Sciences, Ladoke Akintola University of Technology, Department of Internal Medicine; Endocrinology, Diabetes & Metabolism Unit
2. LAUTECH Teaching Hospital, Ogbomoso, Ophthalmology
3. College of Medicine, University of Lagos, Lagos University Teaching Hospital, Idi- Araba, Lagos Department of Medicine, Endocrinology, Diabetes & Metabolism Unit
4. LAUTECH Teaching Hospital, Ogbomoso, Oyo State, Department of Internal Medicine
5. Obafemi Awolowo University, Dept of Medicine

Abstract

Introduction: Diabetes mellitus (DM) afflicts at least 5 million people in Nigeria, with more than 80% having type 2 diabetes mellitus (T2DM). Microvascular complications increase both morbidity and mortality in patients with T2DM. The aims of this study were to report the burden of various microvascular complications in T2DM and to identify various factors associated with these complications in patients with T2DM attending the diabetes outpatients' clinic.

Methods: Ninety (90) patients with T2DM who have attended diabetes clinic for at least 3 months were recruited for this study. Detailed history, physical examination and biochemical analysis was done in each of the patients. All patients underwent a detailed standard evaluation to detect diabetic retinopathy (fundoscopy), neuropathy (10g monofilament and/or diabetes neuropathy scores), and nephropathy (microalbuminuria, macroalbuminuria, serum creatinine and estimated glomerular filtration rate).

Results: There was high prevalence of microvascular complications among patients with T2DM. Almost half of patients with T2DM had some form of microvascular complications; diabetic neuropathy being the commonest (69.6%), followed by nephropathy (54.5%) and retinopathy (48.9%). The factors associated with developing these complications were increasing age, duration of diabetes, hypertension and dyslipidaemia for nephropathy and neuropathy.

Conclusion: There is a high burden of microvascular complications in patients with type 2 diabetes. Age, male gender, hypertension, glycaemic control, BMI and duration of diabetes, and glycaemic control were factors associated with microvascular complications.

Keywords: Type 2 diabetes, microvascular complications, prevalence, risk factors, Nigeria.

DOI: <http://dx.doi.org/10.4314/ahs.v15i4.12>

Cite as: Olamoyegun M, Ibraheem W, Iwuala S, Audu M, Kolawole B. Burden and pattern of micro vascular complications in type 2 diabetes in a tertiary health institution in Nigeria. *Afri Health Sci.* 2015;15(4):1136-41. <http://dx.doi.org/10.4314/ahs.v15i4.12>

Background

Diabetes mellitus (DM) has emerged as one of the most common chronic disorders with an estimated global prevalence of 366 million in 2011 and projected to in-

crease to 551 million in 2030¹. The estimated prevalence of DM in sub-Saharan Africa is about 1% in rural areas, and 5-7% in urban areas, and between 8% and 13% in countries like Uganda and South Africa^{2,4}. In Nigeria, the national prevalence of DM is 2.2%⁵ with a higher prevalence in the urban than in the rural communities. However, studies from different parts of the countries have recorded rates of between 1% and 8%⁶⁻¹⁰. Morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) is mainly attributed to the development of both microvascular and macrovascular complications. These microvascular complications include nephropathy, retinopathy and neuropathy. Hence, the increasing prevalence of T2DM will be followed by an epidemic of diabetes related cardiovascular disease (CVD) espe-

Corresponding author:

Michael Olamoyegun,
LAUTECH Teaching Hospital,
and College of Health Sciences,
Ladoke Akintola University of Technology,
Department of Internal Medicine;
Endocrinology, Diabetes & Metabolism Unit,
Email: dryemi@yahoo.com /
dryemimike@gmail.com

cially microvascular complications. Identifying contributing factors of these diabetes complications makes it possible to control these complications and can lead to significant reduction in morbidity, mortality and health care cost.

Diabetic nephropathy is an increasingly common cause of end stage renal disease (ESRD) in many countries including Nigeria¹¹; the prevalence of nephropathy in Nigerian patients with T2DM rose from 7% in 1963 to 56.5% in 1999¹²⁻¹⁴. The earliest clinical evidence of nephropathy is occurrence of microalbuminuria (30-300mg/day), and its presence has been shown to be associated with increased risk of cardiovascular morbidity and mortality in T2DM patients^{15,16}. DM retinopathy on the other hand is the most common microvascular complications in diabetes and it may lead to blindness ultimately¹⁷. It may manifest as retinopathy lesions as microaneurysm, haemorrhage, cotton wool spots, hard exudates¹⁸. Presence of retinopathy, apart from increasing risk of vision loss, also increased cardiovascular disease by 2-3 folds¹⁹. Hence, this study aimed at identifying prevalence and risk factors influencing predisposition to microvascular complications in type 2 diabetic patients.

Methods

This cross-sectional study was conducted at LAUTECH Teaching Hospital, Ogbomoso. A convenient sample of ninety-two patients with T2DM aged 40 years and above were consecutively recruited from the diabetic clinic between January and May, 2013. Inclusion criteria was known patients with type 2 diabetes who had been attending the diabetes clinic for at least 3 months and willing patients. Exclusion criteria included patients with type 1 DM and pregnant women.

Patients provided written informed consent. The study was approved by the local ethical committee and conducted in accordance with the principles described in the declaration of Helsinki.

An interviewer administered questionnaire was used to collect data on the following variables from the patients: age, gender, duration of diabetes, body weight (kg), height (m), waist and hip circumferences (cm), systolic (SBP), and diastolic blood pressure (DBP), fasting plasma glucose (FPG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides (TG).

Patients' weight and height were measured to the nearest 0.1kg and 0.1cm with a standardised stadiometer and weighing scale, respectively²⁰. BMI was calculated as weight divided by height squared (kg/m^2). Waist circumference (WC) was recorded as the smallest girth between the rib cage and the iliac crest²¹. SBP and DBP were measured in the Patients after a 5-minute rest using digital sphygmomanometer (Omron). Hypertension was defined as the need for antihypertensive therapy or untreated patients with $\text{SBP} \geq 140\text{mmHg}$ and/or $\text{DBP} \geq 90\text{mmHg}$ ²².

The Patients were evaluated for the presence of any these microvascular complications i.e. retinopathy, nephropathy and neuropathy, either alone or in combination. Ophthalmoscopic examination was performed by an experienced ophthalmologist by fundoscopy and direct ophthalmoscopy. Retinopathy was diagnosed by the presence of any of the following lesions: microaneurysm, blot or flame-shaped haemorrhage, hard exudates, cotton wool spots or macula oedema²³. Nephropathy was diagnosed when serum creatinine was $> 150\text{microgram}/\text{dl}$, estimated glomerular filtration rate (eGFR) is $< 60\text{ml}/\text{min}$, and/or presence of proteinuria or microalbuminuria²⁴. Neuropathy was diagnosed by history of numbness, parasthesia, tingling sensation, loss of ankle reflex or loss of light touch sensation using 10-gram monofilament²⁵.

Blood sample was taken for biochemical parameters after an overnight fast of 8-14hours. This was used for fasting plasma glucose (FPG) estimation by a glucose oxidase method²⁶. Total cholesterol (TC), HDL-C and triglycerides by enzymatic methods, and LDL-C were calculated by using Friedwald equation²⁷. Patients with untreated total cholesterol $> 5.0\text{mmol}/\text{l}$, $\text{TG} > 1.7\text{mmol}/\text{l}$ and/or $\text{HDL-C} < 1.01\text{mmol}/\text{l}$ (in males) and $< 1.29\text{mmol}/\text{l}$ (in females) were considered to have dyslipidaemia²⁸. Glycated haemoglobin (HbA1c) was tested by in2it®. Data was expressed as means \pm SD. Statistical analysis was performed using SPSS (version 17.0 Chicago, SPSS Inc.). A Student's t-test for unpaired sample was used to compare means with standard deviations (SD), and a Chi-square to compare proportions. Statistical significance was set at $p < 0.05$. Regression analyses were performed for finding factors associated with various complications. Logistic regression analysis was used to find out strength of association of risk factors with specific complications.

Results

The total study participants included equal number of males and females (46). The mean age of the partici-

pants 62.5 ± 8.6 years and the duration of diabetes was between 1 and 30 years, and median duration of 8 years. The demographic profile is shown in table 1.

Table 1: Demographic and biochemical profile of study population

Parameter	Mean \pm SD
Age (years)	62.54 \pm 8.62
LDL (mmol/L)	2.46 \pm 1.02
TG (mmol/L)	0.74 \pm 0.33
HDL (mmol/L)	1.10 \pm 0.47
TC (mmol/L)	3.92 \pm 1.23
BMI (kg/m ²)	26.9 \pm 4.40
TC/HDL	3.68 \pm 0.54
LDL/HDL	2.49 \pm 1.21
DBP (mmHg)	83.1 \pm 10.7
SBP (mmHg)	137.5 \pm 18.3
Pulse pressure	54.3 \pm 18.1
Uric acid (mg/dl)	0.33 \pm 0.09
HbA1c (%)	9.76 \pm 2.4
FPG (mmol/L)	10.2 \pm 2.9

Retinopathy was seen in (45/92) 48.9% (higher in females than in males, although the difference was not statistically significant, $p=0.235$). Nephropathy was present in 54.3% (50/92), significantly higher in males than females ($p=0.003$). Neuropathy was present in 69.6% (64/92) participants giving a prevalence of 69.6%.

Nephropathy and neuropathy rates were significantly higher in males, ($p=0.003$) and ($p=0.001$) respectively. Patients with nephropathy and retinopathy had higher blood pressure and mean HbA1c, were older and had longer duration of diabetes ($p=0.0002$). Participants with neuropathy had higher BMI, longer duration of diabetes and higher LDL-C ($p=0.003$), as shown in table 2.

Table 2: Clinical and biochemical profile of the subjects with and without micro vascular complications.

Parameter	With (51)	Without (41)	P-value
Age (years)	62.84 \pm 8.77	62.17 \pm 8.5	0.003
Weight (Kg)	70.1 \pm 11.2	69.9 \pm 10.5	0.020
Total Cholesterol (mmol/L)	4.1 \pm 1.3	3.7 \pm 1.2	0.006
HDL (mmol/L)	1.1 \pm 0.5	1.09 \pm 0.4	0.070
eGFR (ml/min)	53.8 \pm 14.8	55.6 \pm 16.0	0.020
LDL(mmol/L)	2.6 \pm 1.4	2.3 \pm 1.0	0.002

Further analysis of patients' shows 37% of Patients had at different microvascular combinations of varying combination and 23% had all the three microvascular complications together.

On multivariate analysis, at least one of the microangiopathies were associated with older age, as shown in table 3.

Table 3: Logistic regression analyses of Potential Predictors of at least one micro vascular complication

Independent variable	Unadjusted OR(95% CI)	Adjusted OR(95% CI)	p- value
Age	1.2 (1.0-1.4)	1.2(1.0-1.5)	0.032
BMI	1.0(0.8-1.3)	0.9(0.7-1.3)	0.581
Male sex	3.1(0.3-31.4)	10.8(0.6-205.6)	0.115
Systolic blood pressure	1.0(1.0-1.1)	1.0(0.9-1.1)	0.665
Diastolic blood pressure	1.0(0.9-1.1)	1.0(0.1-1.1)	0.867

Discussion

In this hospital-based study, the prevalence of different microvascular complications of diabetes was similar to figures from other populations in Africa^{29,30}, but much higher than those reported by Kumar et al³¹ in India. The reason for this may be due to poor control of glycaemia among our patients; only 41% of our patients had target goal of blood sugar.

In our study, 55.4% of the patients had nephropathy. This is much higher than value obtained by Alebiosu et al³⁴ who obtained 25%. DM nephropathy is now the leading cause of ESRD worldwide and is responsible for about 1/3 of patients who undergo dialysis¹². In Nigeria, DM nephropathy as a cause of nephropathy is also high, representing 15–25%¹¹. As previous studies²⁹⁻³¹, have indicated, this study also found age, hypertension, and male sex as important risk factors for DM nephropathy³⁵.

Retinopathy remains an important complication of diabetes mellitus. The prevalence of retinopathy among Nigerians with T2DM has been estimated to range between 20–56%³⁰, which is similar to the prevalence of 48.9% obtained in this study as also from a study carried out amongst Ghanaians with T2DM. This study documented that age, male sex, duration of diabetes mellitus, hypertension and poor glycaemic control has significant association with DM retinopathy.

Diabetic peripheral neuropathy is very common in T2DM patients. We found DPN in 69.6% of the study participants, which is similar to 71.1% obtained by in other studies done in Nigeria^{36,37}. It is a major risk factor for development of foot ulceration, and increased morbidity and mortality. However, gender, eGFR were not associated with DPN³⁷. Other studies however, have not reported a significant relation between age and the duration of diabetes on DPN³⁸. Diabetic neuropathy is the most common late complication of DM, and some

of the consequences include pain, falls, foot ulceration, sleep impairment, depression, and impaired quality of life³⁹⁻⁴¹.

Also, a significant percentage of our patients did not achieve target blood pressure control of 130/80mmHg. The reason for the poor blood pressure and glycaemic control are usually multifactorial. Financial constraint, lack of regular follow up visit in the clinic and late presentation before diagnosis are some of the factors affecting diabetes management in Nigeria⁴². Most patients have to pay out of pocket for their medical managements including drugs purchase, blood sugar and other laboratory testing, and at a price much higher than the cost of these drugs in other parts of the world³². The WHO report estimates that 90.2% of Nigerians live below poverty level of \$2 per day. Thus, accessing health care is a challenge to people living with diabetes in Nigeria. Also, the high prevalence of complications may be related to the older patients recruited in this study, compared to studies with lower prevalence of complications. Our data shows that the common risk factors for any microangiopathy is old age.

Finally, our data though hospital based revealed high frequencies of microangiopathy complications in our patients. The prevalence and risk of these microangiopathic complications are old age, duration of diabetes, poor glycaemic control, hypertension and increased body mass index among other factors. These factors if controlled will probably lead to reduction in the burden of type 2 diabetes complications.

Limitations

The strength of our study is that although the sample size was modest, the study examined the profile of all microvascular complications in Nigerian patients. Due to the paucity of studies that examines all the profile

of microvascular complications together; it can serve as baseline upon which future studies can be referred. Further prospective observation study with a more robust sample size is recommended for a better result. The limitations of this study included the use of only direct ophthalmoscope in the assessment of DM retinopathy instead of retinal photography; this could have led to better detection of early retinopathy, further increasing the prevalence of retinopathy. Also, the use of biothesiometer for the detection of peripheral neuropathy would have been preferred yielding better diagnosis compared to the use of symptoms scores and microfilament. These instruments were not used for lack of availability and cost associated with the investigations.

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

References

1. Guariguata L, Whiting D, Weil C, Unwin N. The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults. *Diabetes Res Clin Pract.* 2011; 94(3):322-32.
2. Rotimi C, Daniel H, Zhou J, Obisesan A, Chen G, Chen Y et al. Prevalence and determinants of diabetic retinopathy and cataracts in West African type 2 diabetes patients. *Ethn Dis.* 2003; 13(2 Suppl 2):S110-7.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes; Estimates for the year 2000 and projections for 2030. *DiabetesCare.* 2004;27:1047-53.
4. Adekanle O, Ayodeji OO, Olatunde LO, Folorunso TR. A 7-year retrospective study of diabetes-related deaths in a Nigerian tertiary hospital. *Diabetes.* 2008;16:15-17.
5. Akinkugbe OO. Non-communicable Diseases in Nigeria. Final report of a national survey; Federal ministry of Health and Social Services, 1997.
6. Ohwovoriole AE, Kuti JA, Kabiawu SI. Casual blood glucose levels and prevalence of undiscovered diabetes mellitus in Lagos metropolis Nigerians. *Diabetes Res Clin Pract.* 1998; 4(2): 153-8.
7. Dahiru T, Jibo A, Hassan AA, Mande AT. Prevalence of diabetes in a semi-urban community in Northern Nigeria. 2008; 17(4):414-6.
8. Owoaje EE, Rotimi CN, Kaufman JS, Tracy J and Cooper RS. Prevalence of adult diabetes in Ibadan, Nigeria. *East Afr Med J.* 1997; 74(5): 299-302.

9. Rotimi CN, Cooper RS, Okosun IS, Olatunbosun ST, Bella AF, Wilks R, et al. Prevalence of diabetes and impaired glucose tolerance in Nigerians, Jamaicans and US blacks. *Ethn Dis.* 1999; 9(2): 190-200.
10. Nyenwe EA, Odia OJ, Ihekweba AE, Ojule A and Babatunde S. Type 2 diabetes in adult Nigerians: a study of its prevalence and its risk factors in Port Harcourt, Nigeria. *Diabetes Res Clin Pract.* 2003; 62(3): 177-85.
11. Agaba IE, Agbaji OO, Anteyi EA. Pattern of renal disease in North Central Nigeria. *Journal of Medicine in the Tropics.* 2002; 4:33-37.
12. Kinnear TWG. The pattern of diabetes in a Nigerian Teaching Hospital. *East Afr. Med J.* 1963; 40: 288-294.
13. Adetuyibi A. Diabetes in Nigerian African: Review of long- term complications. *Trop. Geog. Med.* 1976; 28: 155- 168.
14. The clinical profile of Nigerians with long- standing diabetes mellitus. *Int Diab Diag* 1998; 9: 44-45.
15. Sasso FC, De Nicola L, Carbonara O, Nasti R, Minutolo R, Salvatore T et al. Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy. *Diabetes Care.* 2006;29(3):498-503
16. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin- dependent diabetes: 10- year observational follow- up study. *Brit Med J.* 1996; 313: 779-84.
17. Klein R, Klein BEK, Moss SE. Epidemiology of proliferative diabetic retinopathy. *Diabetes Care.* 1992; 15: 1875-91.
18. Verma L, Prakash G, Tewari HK, Gupta SK, Murthy GV, Sharma N. screening for diabetic retinopathy by non-ophthalmologists: effective public health tool. *Acta Ophthal Scan.* 2003; 81: 373-7.
19. Juutilainen A, Lehto S, Ronnema T, Pyorala K, Laakso M. retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. *Diabetes Care.* 2007; 30: 292-9.
20. Cawley J, Burkhauser RV. BEYOND BMI: The value of more accurate measures of fatness and obesity in social science research. National bureau of economic research, 1050 Massachusetts Avenue, Cambridge, MA 02138. June 2006. Working Paper 12291. <http://www.nber.org/papers/w12291>
21. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva. 2008; 8-11
22. Luehr D, Woolley T, Burke R, Dohmen F, Hayes R, Johnson M, Kerandi H, Margolis K, Marshall M, O'Connor P, Pereira C, Reddy G, Schlichte A, Schoen-

- leber M. Institute for Clinical Systems Improvement. Hypertension Diagnosis and Treatment. <http://bit.ly/Hypertension1112>. Updated November 2012
23. M Rodgers, Hodges R, Hawkins J, Hollingworth W, Duffy S, McKibbin M, Mansfield M, Harbord R, Sterne J, Glasziou P, Whiting P and Westwood M. Colour vision testing for diabetic retinopathy: a systematic review of diagnostic accuracy and economic evaluation. *Health Technology Assessment* 2009; 13(60) DOI: 10.3310/hta13600
24. Feldt-Rasmussen B. Screening and diagnosis of diabetic nephropathy. *DiabetesVoice*. 48:12-14
25. Hsieh ST. Pathology and Functional Diagnosis of Small-fiber Painful Neuropathy. *Acta Neurol Taiwan* 2010;19:82-89 PubMed
26. Muktabhant B, Sanchaisuriya P, Sarakarn P, Tawitayanon W, Trakulwong M, Worawat S, Schelp FP. Use of glucometer and fasting blood glucose as screening tools for diabetes mellitus type 2 and glycated haemoglobin as clinical reference in rural community primary care settings of a middle income country. *BMC Public Health* 2012 12:349. PubMed doi:10.1186/1471-2458-12-349
27. Chen Y, Zhang X, Pan B, Jin X, Yao H, Chen B, Zou Y, Ge J and Chen H. A modified formula for calculating low-density lipoprotein cholesterol values *Lipids in Health and Disease* 2010, 9:52. doi: 10.1186/1476-511X-9-52.
28. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA, and the AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis. American association of clinical endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. *Endocrine practice*. 2012;18(1): 1 PubMed -78
29. Hillis GS, Hata J, Woodward M, Perkovic V, Arima H, Chow CK et al. Resting Heart Rate and the Risk of Microvascular Complications in Patients With Type 2 Diabetes Mellitus. *J Am Heart Assoc*. 2012;1(5):e002832.
30. Tesfaye S and Gill G. Chronic diabetic complications in Africa. *African Journal of Diabetes Medicine*. 2011;19(1): 4-8
31. Hari Kumar KVS, Kota SK, Basile A, Modi KD. Profile of microvascular disease in Type 2 Diabetes in a tertiary health care hospital in India. *Annals of Medical and Health Sciences Research*. July 2012; 2(2): 103 PubMed -108.
32. Okoro EO, Adejumo AO, Oyejoba BA. Diabetic care in Nigeria: report of a self-audit. *J. Diabetes complications*. 2002; 16; 159 – 64.
33. Uloko AE, Yusuf SM, Puppert FH, Adeniyi AF, Gezuwa ID, Sada KB et al. Assessment of quality of glycaemic control and clinical complications of DM. *Arch Diab & Cardio Med*. 2012; 1(4): 40 – 45.
34. Alebiosu CO. Clinical diabetic nephropathy in a tropical African population. *West Afr J Med*. 2003; June, 22(2): 152-155.
35. Usman A, Umar RA, Shehu NI, Wali U and Nasir A. Markers of Diabetic Nephropathy in Diabetic Patients in Gusau, Zamfara State, Nigeria. *Nigerian Journal of Basic and Applied Science* 2012;20(2): 130-133. <http://www.ajol.info/index.php/njbas/index>
36. Owolabi MO, Ipadeola A. Total vascular risk as a strong correlate of severity of diabetic peripheral neuropathy in Nigerian Africans. *Ethn Dis*. 2012;22(1):106-12
37. Ugoya SO, Echejoh GO, Ugoya TA, Agaba EI, Puepet FH, Ogunniyi A. Clinically diagnosed diabetes neuropathy: frequency, types, and severity. *J Natl Med Assoc*. 2006; 98(11): 1763 PubMed - 1766.
38. Booya F, Bandarian F, Larijani B, Pajouhi M, Nooraei M, Lotfi J. Potential risk factors for diabetic neuropathy: a case control study. *BMC Neurol*. 2005;5:24.
39. Sima AA. Pathological mechanisms involved in diabetic neuropathy: can we slow the process? *Curr Opin Investig Drugs*. 2006; 7(4):324–337.
40. Zelman DC, Brandenburg NA, Gore M. Sleep impairment in patients with painful diabetic peripheral neuropathy. *Clin J Pain*. 2006; 22(8):681–5.
41. Vileikyte L, Leventhal H, Gonzalez JS, Peyrot M, Rubin RR, Ulbrecht JS et al. Diabetic peripheral neuropathy and depressive symptoms: the association revisited. *Diabetes Care*. 2005;28(10):2378-83
42. Nwankwo CH, Nandy B and Nwankwo BO. Factors Influencing Diabetes Management Outcome among Patients Attending Government Health Facilities in South East, Nigeria. *International Journal of Tropical Medicine*. 2010;5: 28-36 PubMed . DOI: 10.3923/ijtm.2010.28.36.